Centus Biotherapeutics
http://www.centusbiotherapeutics.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Centus Biotherapeutics
AstraZeneca-Backed JV Sued By Genentech Over Avastin Biosimilar
With the US biosimilar Avastin market now more than a year old, another potential player, Centus Biotherapeutics, finds itself facing trial over its biosimilar candidate. The UK-based joint venture already boasts approval from the European Commission for its FKB238 product, Equidacent.
Centus Gets European Bevacizumab Approval
Centus Biotherapeutics has received formal European Commission approval for its Equidacent biosimilar rival to Avastin.
EMA Says Yes To GSK’s Belantamab But Rejects Tagraxofusp & Emapalumab
GlaxoSmithKline's first-of-its kind treatment for multiple myeloma is among 11 new medicines that have won an EU approval nod from the European Medicines Agency this week.
Company Information
- Industry
- Biotechnology
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice